ArticlePloS one2026
integrating single-cell transcriptomics and chromatin accessibility profiling to decipher the molecular landscape of Hepatocellular carcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a prevalent and lethal liver malignancy, characterized by high recurrence rates and limited therapeutic options. Current diagnostic and treatment strategies are hindered by drug resistance and a lack of effective biomarkers for early detection.
methodsThis study aims to elucidate the role of lactylation and fibroblast cells within the tumor microenvironment (TME) of HCC, focusing on their potential as therapeutic targets. Utilizing a comprehensive multi-omics approach, we integrated single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) data from public databases (GEO, TCGA) to explore transcriptional and epigenetic landscapes at single-cell resolution.
resultsOur analysis identified fibroblast cells as key players with high lactylation-related pathway activity, and CREB1 as a central transcription factor regulating lactylation-associated genes in these cells. The CREB1 regulatory network was associated with specific immune cell infiltration patterns, drug sensitivity profiles, and enrichment in critical signaling pathways such as Chemokine, TNF, NF-κB, and EMT. These findings underscore the pivotal role of lactylation-driven epigenetic regulation in fibroblasts, influencing the HCC immune microenvironment and disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.